用凝封装的胰腺小岛细胞作为糖尿病细胞治疗的有希望的策略
Zhikun Huan1, Jingbo Li1, Zhiqiang Luo2
1Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Research (Washington, D.C.)
|July 5, 2024
概括
水凝封装为治疗糖尿病的岛屿细胞疗法提供了一个有前途的策略. 这种方法旨在克服供体短缺和免疫排斥等挑战,以改善患者的治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
- 糖尿病研究 糖尿病研究
背景情况:
- 岛屿移植是胰岛素缺乏糖尿病的有希望的治疗方法,可提供内源性胰岛素补充剂.
- 目前的局限性包括供体稀缺,免疫排斥和低于最佳的移植地点,阻碍了广泛的临床使用.
- 岛屿细胞的凝封装正在成为解决基于细胞的糖尿病治疗这些挑战的关键策略.
研究的目的:
- 审查用于糖尿病细胞治疗的水凝封装胰腺小岛细胞的进展.
- 探索这种治疗方法中使用的各种细胞来源,封装技术和水凝材料.
- 讨论改善移植结果的方法以及未来的前景和挑战.
主要方法:
- 对糖尿病岛屿细胞水凝封装研究的综合文献综述.
- 分析不同的小岛细胞来源 (例如,异构,异构,干细胞).
- 评估各种封装方法,水凝成分和提高移植效率的策略.
主要成果:
- 水凝封装可以保护移植的小岛细胞免受免疫攻击,并提高生存率.
- 量身定制的水凝特性可以增强移植地点的细胞功能和融合.
- 包括生物材料修饰和共同移植在内的各种策略显示出改善治疗结果的潜力.
结论:
- 用凝封装的小岛细胞移植是一种可行的策略,可以克服糖尿病细胞治疗中的重大障碍.
- 进一步研究优化水凝材料,细胞来源和输送方法对于临床转化至关重要.
- 这种方法对恢复葡萄糖平衡和改善糖尿病患者的生活质量具有显著的前景.
相关概念视频
iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...


